Active-ingredient Dossier
Sunitinib Malate
Active-ingredient Dossier for Sunitinib Malate (tyrosine kinase inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: ARX-SUNITINIB
- Brand: SUTENT
- Brand: SUNITINIB MSN
- Therapeutic area: Oncology
What is
Sunitinib Malate Sunitinib Malate is a tyrosine kinase inhibitor.
Australian brands containing
Sunitinib Malate — SUNITINIB MSN — SUTENT — ARX-SUNITINIB
Therapeutic areas
Sunitinib Malate is registered in oncology, with three brands containing this ingredient.
Sponsor landscape
Three sponsors market sunitinib malate in Australia: Arrotex Pharmaceuticals, Accelagen, and Pfizer.
PBS and regulatory activity
The latest PBAC outcome for sunitinib malate was recorded on 1 November 2014, with two brands having PBAC outcomes on record. The latest AusPAR was issued on 24 February 2011, with one brand having an AusPAR on record.